Mounjaro and Ozempic are both injectable weight loss medications that have gained enormous attention in 2025 — but they work differently, produce different results, and are not interchangeable. Understanding the distinction helps you and your physician make the right choice for your health goals.
How They Work: GLP-1 vs. Dual GIP + GLP-1
Ozempic (semaglutide) is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a hormone released from the gut after eating. GLP-1 signals satiety to the brain, slows gastric emptying, and suppresses glucagon release — all of which reduce appetite and improve blood sugar control. It is injected once weekly.
Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist — the first of its kind. GIP (glucose-dependent insulinotropic polypeptide) is another gut hormone that plays a role in fat metabolism, insulin secretion, and appetite regulation. By activating both GIP and GLP-1 pathways simultaneously, tirzepatide engages a broader hormonal response than semaglutide alone.
In practical terms, this dual mechanism is why tirzepatide tends to produce greater weight loss than semaglutide. You are getting two complementary hormonal effects working together rather than one.
Clinical Trial Results
The head-to-head data is compelling. Here is how the two medications compare in their landmark clinical trials:
The SURMOUNT-1 trial for tirzepatide was a watershed moment in obesity medicine. Participants on the highest dose (15 mg) lost an average of 22.5% of body weight over 72 weeks — results that had never been seen with any previous anti-obesity medication. For context, a 250-pound person losing 22.5% would reach approximately 194 pounds.
Side Effects: What to Expect
Because both medications affect the GLP-1 pathway, they share a largely overlapping side effect profile. Gastrointestinal side effects are the most common for both, particularly during the dose titration period:
Common Side Effects (Both)
Rare but Serious (Both)
Mounjaro's additional GIP activity does not appear to introduce meaningfully different side effects. In clinical trials, the tolerability profiles were similar — though some patients find that one medication is better tolerated than the other on an individual basis.
Both medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2). Your physician will screen for these and other contraindications before prescribing either medication.
Which Is Right for You?
There is no universally correct answer — the right choice depends on your medical history, blood sugar status, prior medication experience, insurance coverage, and weight loss goals. A few general considerations:
You have type 2 diabetes:
Both are indicated. Your physician may prefer one based on your A1C, cardiovascular risk factors, and current medications.
Your primary goal is maximum weight loss:
Tirzepatide (Mounjaro / Zepbound) has demonstrated superior average weight loss in clinical trials, especially at higher doses.
You have tried semaglutide before:
Tirzepatide's different mechanism may produce better results for some patients who have had partial responses to semaglutide.
Cost is a major concern:
Compounded versions of both are available through Soboba. Your physician can discuss pricing options at your consultation.
The Bottom Line
Both Mounjaro and Ozempic represent genuine breakthroughs in medical weight loss. They are not diet pills or gimmicks — they are prescription medications that work at a hormonal level to address the biology of obesity. But they require physician oversight to be used safely and effectively.
Soboba Medical Weight Loss offers both semaglutide and tirzepatide programs at our Newport Beach, Laguna Hills, and Rancho Santa Margarita clinics. Free physician consultation, no startup fees, no contracts. Call us today to find out which option is the best fit for your health and goals.
Sources
- Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." N Engl J Med. 2021;384(11):989–1002. nejm.org
- Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." N Engl J Med. 2022;387(3):205–216. nejm.org
- U.S. Food and Drug Administration. "FDA Approves New Medication for Chronic Weight Management." November 2023 (tirzepatide / Zepbound). fda.gov